PT-141 Dosage Protocol | PeptideDosages.com
PT-141 (10 mg Vial) Dosage Protocol PT-141 Dosage Chart PT-141 is dosed at 500 mcg–1.5 mg daily via subcutaneous injection in educational protocols. A 10 mg vial reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research
PT-141 (10 mg Vial) Dosage Protocol
PT-141 Dosage Chart
PT-141 is dosed at 500 mcg–1.5 mg daily via subcutaneous injection in educational protocols. A 10 mg vial reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.
Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
Typical daily range: 500–1500 mcg once daily (gradual titration over 16 weeks).
Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
PT-141 (bremelanotide) is a synthetic cyclic heptapeptide and non-selective melanocortin receptor agonist (MC3R/MC4R) derived as an active metabolite of Melanotan II[1]. FDA-approved in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women[2], bremelanotide enhances sexual desire by activating MC4R in brain reward and arousal pathways, increasing dopamine release in the nucleus accumbens and medial preoptic area[3]. This educational protocol presents a once-daily subcutaneous approach with gradual titration using a practical dilution for clear insulin-syringe measurements.
Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read PT-141 Peptide: Benefits, Uses, Side Effects, Dosage, and Research.
Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
Weeks 1–8
500 mcg (0.5 mg)
15 units (0.15 mL)
Weeks 9–12
1000 mcg (1.0 mg)
30 units (0.30 mL)
Weeks 13–16
1500 mcg (1.5 mg)
45 units (0.45 mL)
Route & Frequency: Inject once daily subcutaneously (abdomen or thigh). The subcutaneous route provides approximately 100% bioavailability and is better tolerated than intranasal delivery[3]. The FDA-approved on-demand regimen uses 1.75 mg SC before intercourse (max 8 doses/month)[3]; however, daily protocols at 2.5 mg have been studied in obese women for appetite and weight reduction[4], suggesting daily use can be tolerated. This schedule uses a conservative titration starting below the FDA on-demand dose.
Reconstitution Steps
Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Supplies Needed
Plan based on an 8–16 week daily protocol with gradual titration.
Peptide Vials (PT-141, 10 mg each):
8 weeks (56 days × 500 mcg = 28 mg) ≈ 3 vials
12 weeks (56 × 500 + 28 × 1000 = 56 mg) ≈ 6 vials
16 weeks (56 × 500 + 28 × 1000 + 28 × 1500 = 98 mg) ≈ 10 vials
Insulin Syringes (U-100):
Per week: 7 syringes (1/day)
8 weeks: 56 syringes
12 weeks: 84 syringes
16 weeks: 112 syringes
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
8 weeks (3 vials): 9 mL → 1 × 10 mL bottle
12 weeks (6 vials): 18 mL → 2 × 10 mL bottles
16 weeks (10 vials): 30 mL → 3 × 10 mL bottles
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
Per week: 14 swabs (2/day)
8 weeks: 112 swabs → recommend 2 × 100-count boxes
12 weeks: 168 swabs → recommend 2 × 100-count boxes
16 weeks: 224 swabs → recommend 3 × 100-count boxes